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Abstract 
FGF ligands and FGF receptor 1 (FGFR1) appear associated with the nucleus in addition to their extracellular nd transmembrane 
locations. After receptor-dependent internalization in liver cells, radiolabeled 16-kDa FGF-1 appears in a 40-kDa covalent complex with a 
cellular protein. In this repol~:, we show that in a human hepatoma cell line, HepG2, which expresses both FGFR4 and FGFR1, the 
40-kDa complex cross-reacts with antibodies against the ectodomain ofboth types of receptors. In addition to antibody against FGF-1, a 
polyclonal antiserum against the three immunoglobulin (Ig)-like loop ectodomain ofFGFR4 and a monoclonal ntibody to a 19-residue 
sequence in the NH2-terminus of the NH2-terminal Ig Loop I of the three loop splice variant of FGFR1 (FGFR1 a) reacts with the 
complex. A monoclonal ntibody against an epitope in FGFR1 downstream of the inter-loop I/ I I  sequence which reacts with intact 
FGFR1 failed to cross-react with the 40-kDa complex. Cell fractionations and indirect immunofluorescent localization revealed that the 
40-kDa complex associates with the particulate fraction of cells, particularly the nucleus and associated cytoskeletal e ements. We 
propose that he NH2-terminal Ig-loop of the three loop isoforms of FGFR, which are generally associated inversely with cell growth, 
may play a role at or in the nucleus in addition to modification of affinity of the FGFR ectodomain for heparan sulfate and FGF ligand. 
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1. Introduction 
Fibroblast growth factor-1 (FGF- 1) mediates receptor- 
dependent mid-to-late G1 events in the cell cycle which 
correlate with association of both FGF- 1 and the three loop 
a isoform of the intact FOF receptor tyrosine kinase type 
1 (FGFR1) with the nucleus of NIH3T3 mouse fibroblasts 
and L6 rat myoblasts [1] Previously, we reported that 
internalized radiolabeled FGF-1 (16-kDa) appears in a 
40-kDa complex with a cell-derived component in well- 
differentiated human hepatoma cells (HepG2) and rat hep- 
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atocytes [2,3]. Appearance of the complex was receptor- 
dependent and blocked by agents that inhibited ligand-re- 
ceptor internalization. Alternate splicing of an exon coding 
for an NH2-terminal immunoglobulin(Ig)-like disulfide 
loop in the heparin binding fibroblast growth factor recep- 
tor (FGFR) types one and two result in isoforms with 
ectodomains of three and two Ig loops that have been 
designated as a and /3 isoforms, respectively [4]. In 
contrast, FGFR4 appears to express only the three loop a 
isoform [5] and only the a isoform of the FGFR3 gene has 
been reported to date [6,7]. Relative to Loops II and III, the 
sequence of the NH2-terminal loop I is least conserved 
among the four FGFR genes [8]. Although Ig Loops II and 
III are qualitatively sufficient for binding of FGF and 
heparan sulfate [4,9,10], Loop I is interactive with the base 
two loop structure and lowers its affinity for both FGF and 
glycosaminoglycan [11,12]. Here we show that the 40-kDa 
complex from HepG2 cells cross-reacts with antibodies 
raised against he ectodomains of FGFR4 and FGFR1 in 
addition to antibodies against FGF-1 reported earlier [2,3]. 
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Differential reaction with monoclonal antibodies against 
specific epitopes in the FGFR1 ectodomain suggests that 
the cell-derived component of the 40-kDa complex may 
contain all or part of the unique NH2-terminal Loop I of 
the FGFR isoforms and that the complex associates with 
the nucleus and cytoskeletal structures radiating out from 
it. 
2. Materials and methods 
2.1. Formation and detection of 125I-labeled 40-kDa com- 
plex 
The 40-kDa complex containing ~25I-labeled FGF-1 
(125I-FGF-1) was generated by modification of a previ- 
ously published procedure [2]. Briefly, cells (5-7.5 X 10 6) 
attached in monolayer to 25 cm 2 tissue culture dishes were 
incubated in 1.5 ml of binding buffer (RITC 80-7 medium, 
0.1 mM dithiothreitol, 1 mg/ml BSA, 8 /xg/ml heparin) 
containing 8 ng/ml of 125I-FGF-1 (spec. act. 2.5-3.5 X 105 
cpm/ng) ovemight at 37°C (10-12 h). Cells were washed 
once with phosphate-buffered (pH 7.2) saline (PBS) con- 
taining 250 /xg/ml heparin, twice with PBS, then a solu- 
tion of 1 mM disuccinimidyl suberate (DSS) was added for 
10-15 min and the monolayers were again washed twice 
with PBS. The cells were then removed from the dishes by 
scraping into 1.5 ml of ice-cold PBS containing a pro- 
teinase inhibitor mixture (5 /zg/ml leupeptin, 5 /xg/ml 
pepstatin A, 1 mM phenylethylsulfonyl fluoride, 2 mM 
EDTA and 5 /xg/ml aprotinin). After centrifugation, the 
cell pellets were extracted on ice for 20 min with 50 /zl of 
cell lysis buffer [PBS containing 1% Triton X-100, 0.1% 
sodium dodecyl sulfate (SDS) and the proteinase inhibitor 
mixture]. Intact cell-surface FGFR was analyzed in the 
absence of the 40-kDa complex by the same procedure 
after incubation of cells with ~25I-FGF-I at room tempera- 
ture for 90 min. 
2.2. Cell fractionations 
Cell compartments were fractionated according to mod- 
ification of a previously described procedure [13]. Cells 
were pelleted by centrifugation, suspended in five volumes 
of buffer A (10 mM Hepes pH 7.9, 1.5 mM MgC12, 10 
mM KCI and 0.5 mM DTT), disrupted by 10 strokes with 
a glass Dounce homogenizer and then the extract was 
centrifuged at 1000 × g for 10 min. The supernatant was 
designated as the soluble fraction. The pelleted fraction 
was suspended in 5 ml of a 1:1 mixture of buffer C (10 
mM Hepes-KOH at pH 7.6, 1.5 mM MgC12, 10 mM KC1, 
0.5 mM dithiothreitol, 1 mM sodium EDTA, 1 mM sodium 
EGTA) and buffer E (2.4 M sucrose, 15 mM KC1, 2 mM 
sodium EDTA, 0.15 mM spermine, 0.15 mM spermidine, 
0.5 mM dithiothreitol) which was supplemented with pro- 
teinase inhibitors. After ultracentrifugation at 100000 × g 
for 1 h at 4°C, the pellet was washed with PBS containing 
0.5% Triton X-100 and proteinase inhibitors and then 
centrifugated again at 1000 × g for 10 min at 4°C. The 
resulting pelleted material was designated as the particu- 
late fraction assumed to be enriched with nuclei. The 
particulate material was then suspended in 1 ml buffer C 
containing 0.5 M NaC1, disrupted with a Dounce homoge- 
nizer and the resulting extract centrifuged at 100 000 × g 
for 30 min. The supernatant was designated as the nuclear 
extract. The soluble and nuclear extracts were analyzed by 
SDS polyacrylamide g l (8%) electrophoresis (SDS-PAGE) 
and autoradiography as described [2]. 
2.3. Immunoassays 
Immunoprecipitation of FGFR and the 40-kDa complex 
was carried out with isoform-specific mouse monoclonal 
antibodies, M2F12 and M19B2, against FGFR1 [4,9] and a 
polyclonal antiserum A-R4 against the ectodomain of 
FGFR4. A-R4 antiserum was prepared by immunization of 
rabbits with the human FGFR4 ectodomain composed of 
residues 1 to 427 expressed in bacteria as described for 
FGFR1 antigens [4]. Analyses were carried out at 4°C. A 
portion of cell lysate (50 /zl) was diluted to 200 /xl with 
PBS and mixed with 10 /xl of antibody solution for 2 h. 
Ten /zl of protein-A immobilized on agarose beads 
(Pharmacia Biotech, Piscataway, NJ) was then incubated 
with the mixture for 10 h, the beads were collected by 
centrifugation followed by an extensive wash with PBS 
and then cell lysis buffer at a ratio of 1:3 vol/vol. The 
beads were then extracted with SDS-PAGE sample buffer 
and analyzed by SDS-PAGE and autoradiography. 
2.4. lmmunohistochemistry 
Monolayers of HepG2 cells were prepared on 2-cham- 
ber tissue culture slides (Nunc, Naperville, IL), and which 
were coated with a 10 /~g/ml solution of collagen (Life 
Technologies, Grand Island, NY) in PBS before introduc- 
tion of cells. The medium was replaced with 1.5 ml of 
binding buffer containing 8 ng/ml of unlabeled FGF-1 for 
90 min at room temperature or overnight for 10-12 h at 
37°C as indicated. Cells were washed with PBS, cross-lin- 
ked with DSS, and fixed with 3% paraformaldehyde for 30 
min on ice. Plasma membranes and cytosol were removed 
while leaving the attached cytoskeleton and nuclei by 
treatment with PBS containing 0.5% Triton X-100 for 10 
min at room temperature prior to fixation. The fixed 
samples were washed with PBS containing 3% BSA (PBS- 
BSA) and then incubated with 0.5 ml PBS-BSA containing 
5 /zl (1/100 dilution) of rabbit pre-immune serum, anti- 
serum A-R4 or mouse monoclonal antibodies for 1 h on 
ice. After washing 4 times for 5 min with ice-cold PBS- 
BSA, bound antibodies were probed with fluorescein-con- 
jugated goat anti-rabbit or anti-mouse IgG (Pierce, Rock- 
ford, IL) at 1/100 dilution for 1 h on ice. The specimens 
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were then washed 4 times with PBS-BSA and analyzed by 
fluorescence microscopy. 
3. Results 
3.1. The FGF-l-labeled 40-kDa complex reacts with anti- 
bodies against he ectodomains of FGFRla and FGFR4 
125I-FGF-1 was incubated with well-differentiated hu- 
man liver HepG2 cells as described [14]. After incubation 
with the covalent affinity cross-linker, DSS, radiolabeled 
receptor complexes were extracted and analyzed by co-pre- 
cipitation with antibodies against the ectodomains of 
FGFR4 and FGFR1 isoforms (Fig. 1A). Rabbit polyclonal 
A-R4 (Metl-Lys 427) 
FGFR4 














Fig. 1. Imrnunoanalysis of ~251-FGF-l-labeled FGFR4, FGFR1 and a 
40-kDa complex in HepG2 cells. Antibody epitopes within FGFR4 and 
FGFR1 a ectodomains are indicated (panel A). The three Ig-like disulfide 
loops I, II and III, the inter-loop II/ I I I  acidic box domain (open box) and 
the transmembrane domain (hatched box) are shown. Rabbit polyclonal 
antiserum A-R4 was raised against he entire ectodomain metl-lys 427 of 
FGFR4. The epitope for mouse monoclonal M2F12 has been mapped to 
within sequence l uS°-ala TM and M19B2 to within sequence prot46-glu j59 
of FGFR1. After incubation of cells with 125I-FGF-1 at room temperature 
for 90 min (panel B) or 37°C for 12 h (panel C), covalent cross-linker 
DSS was added, the cell lysate was then incubated with the indicated 
antibodies and protein A-conjugated beads and the beads were extracted 
and the product analyzed by 8% SDS-PAGE and autoradiography. The 
lane ("lysate") on the right indicates a sample of total cell lysate prior to 
enrichment by immunoprecipitation. 
Fig. 2. Time course of appearance of the 40-kDa complex in soluble and 
particulate (nuclear) fractions of HepG2 cells. Cells were incubated with 
8 ng/ml 125I-FGF-1 at 37°C for the indicated times prior to addition of 
DSS and fractionation and analysis of soluble (panel A) and particulate 
(nuclear) (panel B) fractions as described in Section 2. 
antiserum A-R4 against a bacterially-expressed FGFR4 
product hat spanned the extracellular nd transmembrane 
domains precipitated a labeled band at 140 kDa character- 
istic of the full-length three Ig loop FGFR4 kinase (Fig. 
1B). Less intense bands at 160-kDa which were character- 
istic of the three loop FGFR1 a isoform were precipitated 
with mouse monoclonals M2F12 and M19B2 (Fig. 1B). 
Antibody M2F12 reacts specifically with the FGFRlc~ 
isoform and its epitope has been mapped to within a 
24-residue sequence in the NH2-terminus of Ig Loop I of 
FGFRla [4]. In contrast, monoclonal M19B2 reacts with 
both FGFR1 a and FGFR1/3 isoforms [9]. Cross-reactivity 
with products of partial FGFR1 cDNAs expressed in bacte- 
ria and baculovirus-infected insect cells, proteolytic frag- 
ments of the FGFR1 ectodomain and synthetic peptide 
sequences from FGFR1, indicate that the epitope for mon- 
oclonal M19B2 is between the characteristic acidic box 
sequence and the heparin-binding domain of FGFR1 which 
composes the NH2-terminus of Ig Loop II (Xu et al., 
unpublished data, Fig. 1A). The acidic box is the character- 
istic sequence of acidic amino acid residues between Loop 
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I and Loop II of the three-loop FGFR1 c~ isoform, but is 
the NH2-terminal sequence of the two-loop FGFR1/3 iso- 
form (Fig. 1A). 
~25I-FGF-1 was then incubated with HepG2 cells at 
37°C to generate the labeled 40-kDa complex (Fig. 1C). 
Analysis of lysates of HepG2 cells incubated with FGF-1 
for 10-12 h at 37°C revealed that the 40-kDa complex 
co-precipitated with the A-R4 and M2F12 antibodies, but 
not the M19B2 antibody (Fig. 1C). Addition of extracts of 
insect cells infected with baculovirus bearing FGFR4 and 
FGFR1 a reduced intensity of the labeled 40-kDa bands 
precipitated with the A-R4 and M2F12 antibodies, respec- 
tively (results not shown). Rabbit polyclonal antisera, A50 
and A40, raised against bacterially-expressed FGR1 c~ and 
FGFR1/3 ectodomains, respectively [4], also co-precipi- 
tated the radiolabeled 40-kDa band in addition to full-length 
FGFR1 covalently cross-linked to radiolabeled FGF-1 from 
the HepG2 cell extracts [3]. Several other polyclonal anti- 
bodies [4] against synthetic peptide sequences and mono- 
clonal antibodies [4] against epitopes downstream of the 
inter-Loop I / I I  sequence which reacted with intact full- 
length FGFR1 failed to cross-react with the 40-kDa com- 
plex (results not shown). 
3.2. Presence of FGFR4 and FGFRla antigens in the 
nuclear fraction 
A comparative analysis of ligand-labeled complexes in 
the soluble and particulate (nuclear) fractions of HepG2 
cells after FGF-1 binding and internalization at 37°C re- 
vealed that the intact ligand-receptor complex disappeared 
from the soluble fraction between 5 and 10 h, whereas the 
40-kDa complex accumulated significantly after 5 h, re- 
mained constant at a maximum through 20 h and then 
declined after 30 h (Fig. 2A). During the same period, 
significant levels of only the 40-kDa complex were de- 
tected in the particulate fraction that was enriched with 
nuclei (Fig. 2B). Appearance of the 40-kDa species in the 
nuclear fraction lagged its appearance in the soluble frac- 
tion by at least 2 h. 
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Fig. 3. Indirect immunofluorescent localization of FGFR antigens in intact HepG2 cells. Cells on tissue culture slides were incubated with 8 ng/ml  
unlabeled FGF-1 at 4°C (panel A) or at 37°C for 12 h (panel B), washed, fixed and stained with the indicated primary antisera s described in Section 2. 
FlVl, fluorescent microscopy; PM, same field observed by phase microscopy; serum, normal rabbit serum. 
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Fig. 4. Indirect immunofluorescent a alysis of FGFR antigens in nuclei and cytoskeleton of HepG2 cells. Conditions of analysis were the same as in Fig. 3 
except he cells were extracted with 0.5% Triton X-100 in PBS for 15 min at room temperature prior to fixing and staining. Except those in the middle 
lower panel, all cells were incubated with FGF-1 at 37°C for 12 h. 
Immunohistochemical ', nalysis of intact HepG2 cells 
after incubation with FGF-1 at 4°C with the M19B2 
antibody and a mixture of the A-4 and M2F12 antibodies 
resulted in a dispersed staining pattern over the cells which 
was characteristic of randomly-distributed cell surface re- 
ceptor antigens (Fig. 3A). In contrast, incubation of cells 
with FGF-1 overnight at 37°C and then analysis with the 
mixture of the A-R4 and M2F12 antibodies resulted in an 
intense staining of nuclei and cytoskeletal elements radiat- 
ing out from them (Fig. 3B). The increase in nuclear 
staining in cells incubated with FGF-1 at 37°C was not 
apparent with monoclonal M19B2 or other antibodies 
downstream of the M19B2 epitope that react with full- 
length FGFR1 [4]. Both antibodies A-4 and M2F12 in 
addition to the anti-FGF-1 antiserum L39L intensely stained 
residual nuclei and radial cytoskeletal elements that re- 
mained fixed to the cell culture slides after removal of 
plasma membranes and cytosol with detergent (Fig. 4, top 
panels). The reactivity of antibody M19B2 with the resid- 
ual structures was near the background level resulting from 
either non-immune serum or mouse ascites containing an 
unrelated monoclonal antibody (Fig. 4, bottom panel). 
Omission of FGF-1 during the 37°C incubation reduced 
the staining by the mixture of M2F12 and A-R4 antibodies 
to background (Fig. 4, bottom center). 
4. Discussion 
In contrast o other cytokines, an intact and only par- 
tially-modified FGF-1 persists in intracellular compart- 
ments after internalization via transmembrane r ceptors 
[14-16] and associates with the nuclear fraction during the 
entire G1 period of the cell cycle [17]. Recently it was 
demonstrated in mouse NIH3T3 cells that the intact three 
Ig-loop isoform of the FGFR1 kinase (FGFR1 a)  trafficks 
near the nucleus as early as 2 h after exposure to FGF-1 
and the association reaches a maximum between 4 and 12 
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h [1]. This suggests that the FGFR1 kinase may be in 
proximity to nuclear or perinuclear substrates in addition 
to those assembled on the intracellular domain of the 
transmembrane receptor. In well-differentiated human hep- 
atoma cells and normal rat hepatocytes, radiolabeled 16- 
kDa FGF-1 persists in cells for 6 to 12 h after internaliza- 
tion via transmembrane r ceptors [14] and appears in a 
characteristic 40-kDa complex that is resistant to dissocia- 
tion by denaturing agents [2,3]. Formation of the 40-kDa 
complex was ligand- and receptor-dependent, but distinct 
from the 100- to 160-kDa complexes of intact transmem- 
brane FGFR and FGF-1 which required exposure to a 
covalent affinity cross-linking agent o survive denaturing 
conditions after extraction. Results of experiments o be 
reported in detail elsewhere (Kan et al., unpublished ata) 
indicate that the level of expression of the FGFR4 gene 
exceeds that of FGFR1 in the HepG2 cells and, of the four 
FGFR genes characterized to date, FGFR4 is the main one 
of the four expressed in normal hepatocytes. An analysis 
of expression products coding for the ectodomain of the 
FGFR4 gene by the polymerase chain reaction indicates 
that hepatoma cells and hepatocytes express only one 
species of the FGFR4 ectodomain which consists of three 
Ig loops (Kan et al., unpublished ata). Expression of the 
FGFR1 gene is normally limited to the non-parenchymal 
fraction of normal iver; however, the gene is activated and 
co-expressed with the FGFR4 gene in hepatocyte-derived 
hepatoma cells [18]. Although expression of the FGFR1 
gene in HepG2 cells probably reflects their hepatoma 
origin, the three Ig loop FGFR1 a isoform is expressed at 
levels that exceed that of the two loop FGFR1/3 isoform 
[11]. Here we have shown that the cell-derived component 
of the FGF-l-labeled 40-kDa complex in HepG2 cells 
appears to be composed of fragments of the extracellular 
domain of the FGFR4 and FGFR1 gene products. An 
antibody against he ectodomain of FGFR4 and a mono- 
clonal antibody against a defined epitope in the NH2- 
terminal Ig Loop I of FGFR1 a react with the radiolabeled 
40-kDa complex in addition to antibodies against FGF-1 
[2]. In addition, analysis of cells and subcellular fractions 
with the same antibodies indicated that, relative to intact 
FGFR4 or FGFRI a, the 40-kDa complex is selectively 
associated with the nucleus and perinuclear cytoskeletal 
elements after exposure of cells to FGF- 1 under conditions 
that induce internalization of the transmembrane receptor- 
ligand complex. Preliminary results using confocal micro- 
scopic analysis indicate that a significant portion of the 
antigen is in the same intranuclear compartment ascontrol 
fluorescent DNA dyes. Although trafficking of the intact 
FGFR a kinase to the nucleus after FGF-l-induced inter- 
nalization may occur [ 1 ], the translocation and subsequent 
generation of the unique NH2-terminal fragment of the 
isoforms at or in the nucleus may play an additional role in 
FGF signal transduction. 
The precise molecular structure, the mode of generation 
and function of the 40-kDa complex or components of it 
remain to be established. Reaction of the 40-kDa complex 
with monoclonal M2F12 which is against the NH2-terminus 
of Loop I of FGFR 1 and lack of reaction with monoclonal 
M19B2 which maps between the acidic box and the hep- 
aran sulfate-binding sequence of Ig Loop II of FGFR1 
suggest hat the receptor component of the 40-kDa com- 
plex includes most of Loop I, but does not extend beyond 
the acidic box sequence. This suggests that generation of 
the stable complex which survives reduction and boiling in 
SDS probably requires both a covalent cross-linking event 
between FGF-1 and the NH2-terminal Loop I of FGFR1 a 
and a proteolytic event which cleaves the cross-linked 
complex from intact FGFR1. The cross-linking event must 
occur prior to proteolytic leavage from the intact FGF- 
FGFRa complex since Loop I and the inter-Loop I / I I  
sequence have no intrinsic affinity for FGF [10]. A molec- 
ular characterization f the structure has been hampered by 
restriction of the 40-kDa complex to differentiated hep- 
atoma cells and hepatocytes [2] which exhibit quantities 
that can only be measured by monitoring covalently-linked 
125I-FGF-1. Whether both the covalent cross-linking and 
proteolytic events which allow detection of the complex 
via labeled FGF-1 are limited to differentiated liver cells is 
unclear. 
Although the NH2-terminal Loop I of FGFR a isoforms 
is not required for FGF or heparan sulfate binding to 
FGFR, the NH2-terminal loop is sufficiently interactive 
with adjacent Loops II and III which compose the FGF 
and heparan sulfate binding sites to lower affinity for 
ligand [4,11,12] and heparin [12]. Although a distinct 
function has not been assigned to the inter-loop acidic box 
sequence which may be a part of the 40-kDa complex, a 
part of the inter-loop sequence is required for interaction 
of Loop I with Loops II and III and the lower affinity for 
ligand and heparin that results from the presence of Loop 
I. In multiple systems including human tumors, reduced 
expression of the FGFR a variant is associated with loss 
of growth control and increasing malignancy. The loss of 
expression of both coding sequence for Loop I and the 
acidic box exon in the FGFR2 gene concurrent with loss of 
low affinity receptors occurs during progression of rat 
prostate tumor epithelial cells to malignancy [12,16]. 
Moreover, a significant portion of the abnormally-ex- 
pressed FGFR1 mRNAs exhibiting coding sequence for 
Loop I in malignant rat prostate tumor cells is spliced at an 
alternate donor site that prevents expression of the trans- 
membrane FGFR1 a isoform [19]. The ratio of expression 
of FGFR1/3 to FGFR1 a in human astrocytomas increases 
dramatically with malignant grade [20]. Human pancreatic 
adenocarcinomas overexpress FGFR1/3 compared to nor- 
mal tissues which express predominately the FGFRla 
isoform [21]. Finally, the growth of the well-differentiated 
HepG2 cells used in this study and normal rat hepatocytes 
which express predominantly the a isoforms of FGFR is 
inhibited by high concentrations of FGF-1 in a time course 
correlative to formation of the 40-kDa complex composed 
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of FGF-1 and the NH2-terminus of the FGFRlc~ and 
FGFR4 isoforms [14]. Expression and activity of the 
FGFR t~ isoforms generally correlate with restraints on cell 
growth and mal ignancy and enhanced ifferentiated func- 
tion. We propose that the anique NH2-terminal Ig loops of 
the FGFR a isoforms and potentially the FGF ligands may 
play a role at or in the nucleus in mediating these aspects 
of FGF-1 activity. 
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